Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Low doses of the drug FTY720, also called fingolimod, given to mice once a day for three days eliminated an infection by a virus that can cause meningitis, an inflammation of the membranes surrounding the brain and spinal cord. The findings suggest the drug, which boosted anti-viral immune responses in the mice, may be useful against viruses that cause high-level, long-lasting infections in people such as hepatitis C and HIV, the researchers said. Microbiologist and immunologist John Altman of Emory University in Atlanta, who led the study, said the researchers plan to assess the effects of the drug on other viruses including the monkey version of the AIDS virus. Altman, whose findings were published in the journal Nature, expressed cautious optimism that the drug might work against certain chronic viral infections in people. "We think it's crucial that we do experiments to check it out," Altman said in a telephone interview. The drug is generally considered to be an immunosuppressant that works to restrain the body's natural defenses. That could be helpful in multiple sclerosis, an autoimmune disease in which the immune system attacks body parts as if they were foreign invaders. But one effect of the drug seems to facilitate the immune response, the researchers said. FTY720 among other things traps white blood cells key soldiers in the immune system's fight against infections in the lymph nodes, Altman said. With viral infections, the lymph nodes are where the immune response can get primed and started, Altman said. Some viruses replicate themselves at high levels in lymph nodes, including the human immunodeficiency virus that causes AIDS. They tested the drug against a mouse virus called lymphocytic choriomeningitis, which causes chronic infections by escaping immune responses. "In the absence of treatment (with FTY720) we have an exhausted immune response. In the presence of treatment, we regain a robust cellular immune response," Altman said. Swiss drug maker Novartis said in June two multiple sclerosis patients taking FTY720 in clinical trials had problems with infections and one died, but the role of the drug in the cases was unclear. Novartis plans at the end of 2009 to seek approval by the European Union for FTY720 to treat MS, spokeswoman Valerie Tate said by e-mail. The drug is currently in late-stage trials. Altman said his study was backed by the U.S. government's National Institutes of Health and was not funded by Novartis.
[EX A]: MS drug may work against viral infection: study.

[EX Q]: The latest work, which appears in the journal PNAS, Proceedings of the National Academy of Sciences of the United States of America, also suggests that different policy steps might be needed in that case. "My study essentially shows that the methods used and analyses presented in the original research are insufficient to rule out other explanations (for lower IQ)," said Ole Rogeberg, an economist at the Frisch Centre for Economics Research in Oslo, to Reuters. The Dunedin Multi-disciplinary Health and Development Study is an ongoing report produced by New Zealand's University of Otago, monitoring 1,037 New Zealand children born between April 1972 and March 1973. The study followed them for 40 years. The participants were periodically tested for IQ and other indices including drug taking, and in 2012 clinical psychologist Madeline Meier produced a study saying there was a link between teenage cannabis use and a lower IQ. Researchers in the Meier study compared the IQ trends of people who never smoked cannabis with four groups of those who did: people who smoked, people who scored as dependent in a follow-up survey, those who scored as dependent twice and those who scored as dependent three times. The study found IQ declines increasing "linearly" with cannabis use, Rogeberg wrote in PNAS. The crucial assumption in the Meier study is that cannabis use is the only relevant difference between the groups tested, he said. His use of a simulation model showed that it may be premature to draw a causal inference between marijuana use and falling IQ scores. For one thing, other writing about the Dunedin group on which Meier's study is based suggest that early cannabis use is more common for people with poor self-control, previous conduct problems, and high scores on risk factors linked to low family socioeconomic status, he wrote. Given these factors, young people from lower status families tended to end up in less intellectually demanding environments, whether by choice or by circumstance, which would increase the difference in IQ levels as they aged. "We know that the researchers have measured the IQ of the participants at various ages in childhood - but we don't know if the IQ changes were similar for the different cannabis-using groups before their cannabis use," he told Reuters. "We don't know how much of the change in IQ we can explain by differences in education, jail time, occupational status, etc and whether this affects the estimates in the paper."
[EX A]: Study casts doubt on link between cannabis, teen IQ drop.

[EX Q]: Health officials will conduct tests to determine whether the latest case is related to the previous seven that have been identified since March. Officials at the New Jersey school could not provide the current health status of the student. The latest case comes shortly after the U.S. Food and Drug Administration allowed the university to use an imported vaccine to help control the disease's spread. The past cases at the Ivy League school were caused by the meningococcal bacteria known as serogroup B. State law requires all Princeton students living in dormitories to receive a meningitis vaccine that protects against most strains but not the serogroup B variety, Princeton spokesman Martin Mbugua said in an email. The outbreak of serogroup B meningitis is rare but not the first of its kind in the United States, according to the Centers for Disease Control and Prevention. Bexsero, made by Swiss drugmaker Novartis AG, will be provided to all undergraduate students, graduate students who live in university housing on or off campus, and students and faculty with certain illnesses, such as sickle cell disease, Princeton officials said earlier this week. The FDA has allowed the use of the vaccine at Princeton under an Investigational New Drug application. The federal CDC considers the drug to be safe. "Everyone involved is working hard to organize a potential serogroup B meningococcal disease vaccine campaign as quickly as possible that fits into Princeton University's academic calendar," said CDC spokeswoman Sharon Hoskins. The Princeton inoculation campaign is set to be voluntary for students and is expected to begin in early December, with another event in February, according to the school's website. Federal and New Jersey state health officials have not advised visitors or students to avoid the campus, Mbugua said. Meningitis is a serious disease that is spread through coughing and exchanges of saliva, and people living in dormitories or other crowded living quarters are especially at risk. The most severe cases can result in death, hearing loss, brain damage, kidney disease or amputation of limbs. Symptoms include fever, headaches and stiff neck.
[EX A]:
Eighth Princeton student diagnosed with meningitis.